CA2344690A1 - Fructosamine oxidase: antagonists and inhibitors - Google Patents
Fructosamine oxidase: antagonists and inhibitors Download PDFInfo
- Publication number
- CA2344690A1 CA2344690A1 CA002344690A CA2344690A CA2344690A1 CA 2344690 A1 CA2344690 A1 CA 2344690A1 CA 002344690 A CA002344690 A CA 002344690A CA 2344690 A CA2344690 A CA 2344690A CA 2344690 A1 CA2344690 A1 CA 2344690A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- diabetic
- fructosamine oxidase
- antagonist
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Methods of reducing the consequences of macrovascular and microvascular dama ge in a diabetic patient reliant upon the inhibition and/or antagonism of Fructosamine oxidase in the patient. Inhibition and/or antagonism can involv e the use of copper chelating agents, substrate analogues or hydrazine compoun ds.
Claims (35)
1. A method of treating a mammalian patient (human or otherwise) predisposed to and/or suffering from diabetes mellitus with a view to minimizing the consequences of macrovascular and microvascular damage to the patient (eg. accelerated atherosclerosis, blindness, renal failure, neuropathy, etc.) which comprises, in addition to any treatment in order to control blood glucose levels, at least periodically inhibiting or antagonizing fructosamine oxidase enzyme activity in the patient.
2. A method of clam 1 wherein said inhibition or antagonism occurs as a result of administration or self administration of at least one fructosamine oxidize reaction product inhibitor or antagonist.
3. A method of claim 2 wherein any such inhibitor or antagonist is selected from the groups (i) copper chelating agents (ii) substrate analogue (iii) hydrazine compound.
4. A method of claim 2 wherein said inhibitor or antagonist is taken orally.
5. A method of claim 2 wherein said inhibitor or antagonist is taken orally as part of a regime, whether totally oral or not, which also involves the control of blood glucose levels.
6. A pharmaceutical composition suitable for use in a method of treating a mammalian patient predisposed to and/or suffering from diabetes mellitus with a view to minimizing macrovascular and microvascular damage, said composition comprising a fructosamine oxidase inhibitor or antagonist in conjunction with a suitable carrier therefor.
7. A pharmaceutical composition for reducing macrovascular and microvascular damage in a mammalian patient (including a human) suffering from diabetes mellitus, said composition comprising a fructosamine oxidase inhibitor or antagonist and suitable carrier therefor.
8. The use of a fructosamine oxidase inhibitor or antagonist in the manufacture of a pharmaceutical composition comprising the fructosamine oxidase inhibitor or antagonist and a suitable pharmaceutical carrier therefor and which composition is useful in treating a mammalian patient (human or otherwise) which or who is suffering from diabetes mellitus to reduce macrovascular and microvascular damage.
9. In combination, a pharmaceutical composition of claims 6 or 7 and a pharmaceutical composition effective at lowering blood glucose levels.
10. A method of treating a mammalian patient (human or otherwise) predisposed to and/or suffering from diabetes mellitus, which includes inhibiting or antagonising fructosamine oxidase enzyme activity in the patient with an agent or agents not contraindicated far the patient.
11. A method of claim 10 wherein said agent(s) is or are copper chelating compounds) administered or self administered to the patient.
12. A method of claim 11 wherein said copper-chelating compound is triethylenetetramine dihydrochloride (triene), ethylenediamine tetraacetic acid, o-phenanthroline, or histidine.
13. A method of claim 10 wherein said agents) is or are substrate analogue compounds) administered or self administered to the patient having an amino acid or peptide moiety with a blocked N-terminal amine group.
14. A method of claim 13 wherein said substrate analogue composition is N
acetylcysteine, captopril, or enalapril.
acetylcysteine, captopril, or enalapril.
15. A method of claim 10 wherein said agent(s) is or are hydrazine compounds) administered or self administered to the patient ie: a compound having a -moiety.
16. A method of claim 15 wherein said hydrazine compound is diaminoguanidine, hydralazine, or carbidopa.
17. A dosage unit or pharmaceutical composition for a patient useful in a method of claim 10 comprising (preferably in effective fructosamine oxidase reaction product inhibiting or antagonising amounts - separately or collectively) of a compound (or compounds) being a substrate analogue or a hydrazine compound having an -NHNH2 moiety, or both.
18. A dosage unit or composition of claim 17 which is in an oral dosage form optionally with earners, excipients or, indeed, even other active agents (e.g.
means to lower blood glucose levels).
means to lower blood glucose levels).
19. A regime or dosage unit or pharmaceutical composition for a diabetic or suspected diabetic patient of captopril [whether effective or intended to be effective in controlling blood pressure of the diabetic patient (at least in part) or not] providing for the patient a sufficient fructosamine oxidase inhibiting and/or antagonizing effect to reduce macrovascular and microvascular damage.
20. A regime or dosage unit or pharmaceutical composition for a diabetic patient or suspected diabetic patient of (i) a hydrazine compound and (ii) at lease one other fructosamine oxidase inhibitor and/or antagonist, the mix of (i) and (ii) providing for the patient a sufficient fructosamine oxidase inhibiting and/or antagonizing effect to reduce macrovascular and microvascular damage.
21. A regime ar dosage unit or pharmaceutical composition for a diabetic patient or suspected diabetic patient of (i) acetylcysteine and (ii) at lease one other fructosamine oxidase inhibitor and/or antagonist, the mix of (i) and (ii) providing for the patient a suff dent fructosamine oxidase inhibiting and/or antagonizing effect to reduce macrovascular and microvascular damage.
22. A regime or dosage unit or pharmaceutical composition for a diabetic patient or suspected diabetic patient of (i) hydralazine and (ii) at lease one other fructosamine oxidase inhibitor and/or antagonist, the mix of (i) and (ii) providing for the patient a sufficient fructosamine oxidase inhibiting and/or antagonizing effect to reduce macrovascular and microvascular damage.
23. A method of treating a mammalian patient (human or otherwise) predisposed to and/or suffering from diabetes mellitus which includes inhibiting and/or antagonizing fructosamine oxidase enzyme activity in the patient with either:
(a) acetycysteine and hydralazine, or (b) acetylcysteine and carbidopa.
(a) acetycysteine and hydralazine, or (b) acetylcysteine and carbidopa.
24. A regime or dosage unit or pharmaceutical composition for a diabetic or suspected diabetic patient which includes either:
(i) acetylcysteine and hydralazine, or (ii) acetylcysteine and carbidopa.
(i) acetylcysteine and hydralazine, or (ii) acetylcysteine and carbidopa.
25. The use of co-administration or serial administration of acetylcysteine and hydralazine for the purpose of reducing micro-vascular damage in a mammal.
26. The use of claim 25 wherein said mammal is diabetic.
27. The use of co-administration or serial administration of acetylcysteine and carbidopa for the purpose of reducing microvascular damage in a mammal.
28. The use of claim 27 wherein said mammal is diabetic:
29. A regime or dosage unit or pharmaceutical composition for a diabetic or suspected diabetic patient of the copper chelator, triene, providing for the patient a sufficient fructosamine oxidase inhibiting and/or antagonizing effect to reduce macrovascular and microvascular damage.
30. A method of treating and/or reducing the likelihood of diabetic cataract in a mammal which comprises at least periodically inhibiting and/or antagonising fructosamine oxidase enzyme activity in the mammal.
31. A method of claim 30 which involves the administration or self administration of effective amounts of triethylenetetramine dihydrochloride (triene).
32. A method of treating and/or reducing the likelihood of diabetic cardiomyopathy in a mammal which comprises at least periodically inhibiting and/or antagonising fructosamine oxidase enzyme activity in the mammal.
33. A method of claim 32 which involves the taking or administration of effective amounts of triethylenetetramine dihydrochloride (triene).
34. A method of claim 1, claim 10, claim 30 or claim 32 herein triethylenetetramine dihydrochloride {triene) is administered and/or self administered in concert with another fructosamine inhibitor and/or antagonist or other fructosamine oxidase enzyme inhibitors and/or antagonists.
35. A method of claim 34 wherein said another inhibitor and/or antagonist or other inhibitors and/or antagonists are administered or self administered to elicit a pharmacological effect for another indication yet together with the effect of the triene is or axe effective for treating or ameliorating macrovascular and microvascular damage of such a patient or mammal.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ33208498 | 1998-09-25 | ||
| NZ332084 | 1998-09-25 | ||
| NZ332079 | 1998-09-28 | ||
| NZ33207998 | 1998-09-28 | ||
| NZ33447199 | 1999-03-03 | ||
| NZ334471 | 1999-03-03 | ||
| NZ337042 | 1999-08-03 | ||
| NZ33704299 | 1999-08-03 | ||
| PCT/NZ1999/000161 WO2000018392A1 (en) | 1998-09-25 | 1999-09-24 | Fructosamine oxidase: antagonists and inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2344690A1 true CA2344690A1 (en) | 2000-04-06 |
| CA2344690C CA2344690C (en) | 2011-03-22 |
Family
ID=27484372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2344690A Expired - Fee Related CA2344690C (en) | 1998-09-25 | 1999-09-24 | Fructosamine oxidase: antagonists and inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP2003521453A (en) |
| AU (1) | AU772026B2 (en) |
| CA (1) | CA2344690C (en) |
| DK (1) | DK1115389T3 (en) |
| ES (1) | ES2461195T3 (en) |
| PT (1) | PT1115389E (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017049529A1 (en) * | 2015-09-24 | 2017-03-30 | Innolife Co., Ltd. | A pharmaceutical composition comprising a copper chelating tetramine and the use thereof |
| WO2023276786A1 (en) * | 2021-06-30 | 2023-01-05 | 株式会社村田製作所 | Copper chelator, anticancer agent and prophylactic or therapeutic agent for wilson's disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0321863A (en) * | 1989-06-19 | 1991-01-30 | Shimadzu Corp | Method and apparatus for analyzing triethylene tetramine or the like |
-
1999
- 1999-09-24 CA CA2344690A patent/CA2344690C/en not_active Expired - Fee Related
- 1999-09-24 PT PT99946470T patent/PT1115389E/en unknown
- 1999-09-24 AU AU58871/99A patent/AU772026B2/en not_active Ceased
- 1999-09-24 DK DK99946470.4T patent/DK1115389T3/en active
- 1999-09-24 JP JP2000571911A patent/JP2003521453A/en active Pending
- 1999-09-24 ES ES99946470.4T patent/ES2461195T3/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003521453A (en) | 2003-07-15 |
| ES2461195T3 (en) | 2014-05-19 |
| AU5887199A (en) | 2000-04-17 |
| CA2344690C (en) | 2011-03-22 |
| DK1115389T3 (en) | 2014-05-12 |
| AU772026B2 (en) | 2004-04-08 |
| PT1115389E (en) | 2014-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Toborek et al. | Endothelial cell functions.¶ Relationship to atherogenesis | |
| US7064145B2 (en) | Inhibition of beta cell degeneration | |
| CA2285389A1 (en) | Use of cytoskeletal inhibitors for the prevention of restenosis | |
| IL195055A0 (en) | Phenoxy carboxylic acid compounds and compositions for delivering active agents | |
| EP0783299A4 (en) | Compounds and compositions for delivering active agents | |
| UA40578C2 (en) | Sulfonylaminopyrimidines and pharmaceutical agent based thereon | |
| CA2221730A1 (en) | Use of angiotensin ii type 2 receptor agonists in tissue repair | |
| AU2274201A (en) | Compounds and compositions for delivering active agents | |
| PL347671A1 (en) | Compounds and compositions for delivering active agents | |
| MY127082A (en) | Synergistic methods and compositions for treating cancer | |
| NZ244499A (en) | Treating breast or endometrial cancer with antiestrogen plus one of an androgen, a progestin and an inhibitor of sex steroid formation or secretion of prolactin, growth hormone or acth | |
| MXPA01008611A (en) | Compounds and compositions for delivering active agents. | |
| NZ505324A (en) | Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration | |
| CA2566496A1 (en) | Pharmaceutical compositions and methods for peptide treatment | |
| AU3492100A (en) | Oxadiazole compounds and compositions for delivering active agents | |
| CA2042569A1 (en) | Stabilized fgf composition | |
| ES2122015T3 (en) | USE OF URODILATINE IN LUNG AND BRONCHIAL DISEASES. | |
| TW200833321A (en) | Pharmaceutical composition for treating hypertension, diabetes mellitus and cardiovascular diseases | |
| CA2344690A1 (en) | Fructosamine oxidase: antagonists and inhibitors | |
| CA2367107A1 (en) | Methods for limiting scar and adhesion formation | |
| CA2374681A1 (en) | Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection | |
| JP2002510653A5 (en) | ||
| SARDESAI et al. | Proteolysis and bradykinin turnover in endotoxin shock | |
| BG104062A (en) | Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor | |
| Bergamini et al. | Effects of Antilipolytic drugs on hepatic peroxisomes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |